Olaparib
From Proteopedia
(Difference between revisions)
| Line 9: | Line 9: | ||
*[[Mutations in BRCA1/BARD1 RING-domain heterodimer]] | *[[Mutations in BRCA1/BARD1 RING-domain heterodimer]] | ||
*[[Mutations in Brca1 BRCT Domains]] | *[[Mutations in Brca1 BRCT Domains]] | ||
| + | *[[RING Finger Domain of BRCA1 and BARD1 Heterodimer]] | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 06:40, 19 October 2023
| |||||||||||
References
- ↑ Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009 Jul 9;361(2):123-34. PMID:19553641 doi:10.1056/NEJMoa0900212
- ↑ Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O'Connor MJ, Smith GC, Martin NM. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem. 2008 Oct 23;51(20):6581-91. PMID:18800822 doi:10.1021/jm8001263
